1. Executive Session 6:30 - 7:00
   ▪ Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes 7:00 - 7:05
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 7:05 - 7:15
   ▪ Senator Grassley Report
   ▪ CMS Updates
   ▪ Single Formulary

4. Medical Director Update 7:15 - 7:20
   ▪ Clinical Programs Update
   ▪ Prescriber Comments

5. Follow-up Items from Previous Meetings 7:20 - 7:35
   ▪ Citalopram > 40 mg/day
   ▪ Provigil®
   ▪ Started and Stabilized in Mental Health categories (samples)

6. RetroDUR/DUR 7:35 - 7:50
   ▪ Opiate Agonists/Opiate Combination Utilization 2007 - 2011
   ▪ Psychotropic Medication Use in Children SFY 2009 – 2011
   ▪ DUR Edits – Refill Too Soon and Ingredient Duplication

7. Clinical Update: Drug Reviews 7:50 – 8:20
   (Public comment prior to Board action)

   Abbreviated Drug Reviews
   ▪ Lotemax® (loteprednol etabonate 0.5%) Ophthalmic Ointment
   ▪ Nucynta ER® (tapentadol) Extended Release Tablet

   Full New Drug Reviews
   ▪ Brilinta® (ticagrelor) Oral Tablet
   ▪ Firazyr® (icatibant) Prefilled Syringe for Subcutaneous Injection
   ▪ Solesta® Gel Prefilled Syringe for Submucosal Injection
   ▪ Viibryd® (vilazodone hydrochloride) Oral Tablet
8. Therapeutic Drug Classes – Periodic Review 8:20 – 8:30
   (Public comment prior to Board action)
   Class review documents available on DVHA web site 2/21/2012 @ 12 Noon
   - Anti-Fungals - Oral
     - Hepatitis C Medications
       - Hepatitis C Antivirals
       - Hepatitis C Protease Inhibitors (brief discussion – previously reviewed)
       - Interferons
       - Pegylated Interferons

9. New Managed Therapeutic Drug Classes 8:30 – 8:35
   (Public comment prior to Board action)
   - Antihypertensives: Alpha Blockers

10. Review of Newly-Developed/Revised 8:35 – 8:45
    Clinical Coverage Criteria and/or Preferred Products
    (Public comment prior to Board action)
    - Antidepressants: SNRIs

11. General Announcements 8:45 – 8:55
    Selected FDA Safety Alerts
    - Proton Pump Inhibitors – Drug Safety Communication – Clostridium difficile associated diarrhea
    - Tysabri® - Drug Safety Communication – Update of Risk Factors for PML
    - Victrelis® - Drug Safety Communication – Important Drug Interaction with Certain HIV Protease Inhibitors

12. Adjourn 9:00